Quercetin Phytosome (Quercefit®)
Last reviewed
Quercetin Phytosome is quercetin, a natural antihistamine flavonoid, wrapped in a phospholipid carrier that solves quercetin's biggest limitation: terrible absorption. Plain quercetin runs 1-2% bioavailable; Indena's branded Quercefit form delivers about 20 times more quercetin into the bloodstream per milligram, achieving levels relevant for MCAS mast cell stabilization. ZebraThrive uses 300 mg daily in the powder.
At a Glance
Daily Dose
300 mg (Daily Powder)
Key Benefits
How It Works
Quercetin Phytosome is quercetin - the flavonoid known as a natural antihistamine - wrapped in a phospholipid carrier that solves quercetin's biggest problem: terrible absorption. Plain quercetin has bioavailability around 1-2%. Quercefit® (Indena's branded phytosome form) delivers about 20 times more quercetin into your bloodstream per milligram. For MCAS, quercetin is one of the most-studied natural mast cell stabilizers - in head-to-head testing against cromolyn, quercetin matched or beat cromolyn across histamine, prostaglandins, leukotrienes, TNF, and IL-8 release. The phytosome form is the only way to get clinically meaningful quercetin levels at a reasonable dose.
What the Research Shows
The Indena Quercefit® phytosome delivery system delivers about 20x higher quercetin plasma concentrations than plain quercetin per milligram. Free quercetin half-life is short (~3.4-3.8 hours), so steady dosing matters; conjugated quercetin (the form actually circulating) persists longer.
Human pharmacokinetic study, healthy volunteers
Quercefit® delivers approximately 20-fold higher quercetin absorption per milligram vs plain quercetin; free quercetin t½ measured 3.4-3.8 hours
Quercetin Phytosome formulations have human RCT evidence in allergic rhinitis, a closely-related histamine-driven condition with similar pathophysiology to MCAS.
Randomized double-blind placebo-controlled trial, n=66, Japan
Quercetin Phytosome at 200 mg/day significantly improved allergic rhinitis symptoms vs placebo over the trial period
Quercetin Phytosome has been evaluated in randomized clinical trials for early-stage COVID-19, which shares with MCAS and post-viral POTS a mast-cell/cytokine-driven inflammatory pathophysiology.
Randomized clinical trial, early-stage COVID-19
Quercefit® supplementation accelerated symptom resolution and reduced inflammatory markers in early-stage COVID-19 patients
Randomized controlled open-label trial, n=42
Quercefit® reduced time to molecular conversion to SARS-CoV-2 negative; LDH -35.5%, Ferritin -40%, CRP -54.8%, D-dimer -11.9% vs standard of care
Addressing the Triad
Tailored benefits for complex conditions
Quercefit® delivers quercetin to your bloodstream at concentrations that actually engage the mast cell stabilization mechanisms. In side-by-side testing with cromolyn, quercetin matched or beat cromolyn across histamine, PGD2, leukotrienes, TNF, and IL-8 release. It also doesn't develop tachyphylaxis - the rapid loss of effect that limits cromolyn over time. A newer mechanism gets it even closer to home for MCAS: quercetin binds CLM-1 to suppress MRGPRX2-mediated degranulation, the non-IgE pathway that drives many MCAS reactions to medications and contrast dyes. Quercefit gives you actual clinical-grade quercetin levels at a swallowable dose.
Quercefit has the most direct hEDS-relevant collagen data of any ingredient in the formulation. A 2023 study in human uterosacral ligament fibroblasts showed quercetin reduced MMP-1, increased LOX (the cross-linking enzyme), and raised fibrillin-2 expression. A 2025 rat tendon study showed oral quercetin improved every measured biomechanical parameter of healing tendons - failure load, stiffness, ultimate stress, strain. At achievable Quercefit concentrations, quercetin sits in the pro-collagen, MMP-inhibiting range (the dose-response goes anti-fibrotic only at much higher concentrations not reached orally). An unusually well-aligned ingredient for hEDS.
For POTS, Quercefit's relevance is mostly the mast cell layer that overlaps with so many POTS cases. A small human trial showed quercetin improved endothelial function (the responsiveness of the lining of your blood vessels), which could theoretically reduce blood pooling. The strongest documented POTS-relevant case is a 2021 published case report of a post-COVID POTS+MCAS patient who recovered from bed-bound to 85-90% of baseline on quercetin therapy. That's one case, not a trial - but the mechanism map (mast cells, vascular endothelium, anti-inflammatory) lines up with what POTS pathology looks like.
Why We Chose This Form
We use Quercefit® - Indena's quercetin phytosome - because it's the only quercetin form with human pharmacokinetic studies showing 20× higher bioavailability than plain quercetin. The phospholipid carrier (sunflower-derived lecithin, MCAS-safe) wraps the quercetin in a structure your gut absorbs efficiently. This is one of the few cases where the branded form is genuinely non-negotiable - generic 'quercetin phytosome' blends typically achieve only 1.5-2× the absorption of standard quercetin, far below Quercefit's 20× number. Quercefit® is the one mandatory branded sourcing in our formulation. Spec verified by Certificate of Analysis on every batch.
Safety & Interactions
Potential Side Effects
Quercefit shows excellent tolerability in 15+ human clinical studies. Plain quercetin causes paradoxical reactions in 10-15% of MCAS patients (one reason luteolin is often preferred for high-sensitivity profiles); Quercefit has fewer reported paradoxical reactions due to the different delivery vehicle, but the pattern can still occur.
Drug Interactions
Quercetin is a CYP3A4 inhibitor in lab tests; recent human data shows repeated dosing produces CYP3A4 induction (not inhibition) via the PXR receptor, downgrading the ivabradine concern to LOW-MODERATE. For metoprolol and propranolol (CYP2D6 substrates), in vivo human data is mixed; start at standard dose and monitor. Mention to your prescriber when initiating.
Excipients to Avoid
- Soy-derived lecithin carriers (Quercefit uses sunflower lecithin, MCAS-safe)
- Magnesium stearate
- Artificial colors
Safe Excipients
- Sunflower lecithin phospholipid carrier
- HPMC capsules
- Rice flour
- [1]Improved Oral Absorption of Quercetin from Quercetin Phytosome®, a New Delivery System Based on Food Grade LecithinPMID: 30328058
Riva A et al. (2019)
- [2]Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind studyPMID: 35776034
Yamada S et al. (2022)
- [3]Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trialPMID: 36712674
Di Pierro F et al. (2023)
- [4]Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical TrialPMID: 34194240
Di Pierro F et al. (2021)
Common Questions
Written by Ken Chapman, Founder of ZebraThrive. Reviewed and last updated .